scholarly journals Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation

Eye ◽  
2005 ◽  
Vol 20 (8) ◽  
pp. 873-881 ◽  
Author(s):  
J I Patel ◽  
P G Hykin ◽  
M Schadt ◽  
V Luong ◽  
C Bunce ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Pars Plana Vitrectomy ◽  
Randomised Trial ◽  
Diabetic Macular Oedema ◽  
Pars Plana

scholarly journals Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations

Eye ◽  
2005 ◽  
Vol 20 (6) ◽  
pp. 674-680 ◽  
Author(s):  
J I Patel ◽  
P G Hykin ◽  
M Schadt ◽  
V Luong ◽  
F Fitzke ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Pars Plana Vitrectomy ◽  
Diabetic Macular Oedema ◽  
Pars Plana

scholarly journals Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e043371
Author(s):  
Wenbin Zheng ◽  
Shida Chen ◽  
Xiaohu Ding ◽  
Kunbei Lai ◽  
Sainan Xiao ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Randomised Controlled Trial ◽  
Pars Plana Vitrectomy ◽  
Controlled Trial ◽  
Diabetic Macular Oedema ◽  
Panretinal Photocoagulation ◽  
Progression Rate ◽  
Thickness Change ◽  
Pars Plana ◽  
Randomised Controlled

IntroductionDiabetic retinopathy (DR) is the main cause of adult visual impairment worldwide. Severe non-proliferative DR (sNPDR) is an important clinical intervention stage. Currently, panretinal photocoagulation (PRP) is the standard treatment for sNPDR. However, PRP alone cannot completely prevent NPDR progression. One explanation might be that PRP does not remove the detrimental vitreous that plays an important role in DR progression. Microinvasive pars plana vitrectomy (PPV) was shown to be a safe and effective method to treat late-stage proliferative DR (PDR) by completely removing the pathological vitreous. However, whether PPV is effective in controlling sNPDR remains unknown. In this trial, we aim to compare the effectiveness of microinvasive PPV with that of PRP for sNPDR progression control.Methods and analysisThis single centre, parallel group, randomised controlled trial aims to evaluate the clinical efficacy of microinvasive PPV in preventing the progression of sNPDR compared with PRP. A total of 272 adults diagnosed with sNPDR will be randomised 1:1 to the microinvasive PPV and PRP groups. The primary outcome is the disease progression rate, calculated as the rate of sNPDR progressed to PDR from baseline to 12 months after treatment. The secondary outcomes include the change in best-corrected visual acuity, re-treatment rate, diabetic macular oedema occurrence, change in central retinal thickness, change in the visual field, cataract occurrence and change in the quality of life.Ethics and disseminationThe Ethics Committee of Zhongshan Ophthalmic Center approved this study (2019KYPJ108). The results will be presented at scientific meetings and submitted for publication to peer-reviewed journals.Trial registration numberNCT04103671.

scholarly journals Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations

2006 ◽  
Vol 91 (3) ◽  
pp. 345-348 ◽  
Author(s):  
M. Gutfleisch ◽  
G. Spital ◽  
A. Mingels ◽  
D. Pauleikhoff ◽  
A. Lommatzsch ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Pars Plana Vitrectomy ◽  
Cystoid Macular Oedema ◽  
Intravitreal Triamcinolone ◽  
Pars Plana

scholarly journals Inflammation and Macular Oedema after Pars Plana Vitrectomy

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Vito Romano ◽  
Martina Angi ◽  
Fabrizio Scotti ◽  
Renata del Grosso ◽  
Davide Romano ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Pars Plana Vitrectomy ◽  
Extracellular Fluid ◽  
Cystoid Macular Oedema ◽  
Therapeutic Approaches ◽  
Fluid Accumulation ◽  
Primary Defect ◽  
Blood Retinal Barrier ◽  
Vasogenic Oedema ◽  
Pars Plana

Cystoid macular oedema (CMO) is a major cause of reduced vision following intraocular surgery. Although the aetiology of CMO is not completely clarified, intraocular inflammation is known to play a major role in its development. The macula may develop cytotoxic oedema when the primary lesion and fluid accumulation occur in the parenchymatous cells (intracellular oedema) or vasogenic oedema when the primary defect occurs in the blood-retinal barrier and leads to extracellular fluid accumulation (extracellular oedema). We report on the mechanisms of CMO formation after pars plana vitrectomy and associated surgical procedures and discuss possible therapeutic approaches.

scholarly journals Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab

Eye ◽  
2019 ◽  
Vol 33 (6) ◽  
pp. 930-937 ◽  
Author(s):  
S. James Talks ◽  
◽  
Devangna Bhatia ◽  
Geeta Menon ◽  
Abosede Cole ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Randomised Trial ◽  
Diabetic Macular Oedema ◽  
Wide Field
Sign in / Sign up

Export Citation Format

Share Document